Research ArticleArticle
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial
Edward C. Keystone, Mark C. Genovese, Stephen Hall, Sang-Cheol Bae, Chenglong Han, Timothy A. Gathany, Stephen Xu, Yiying Zhou, Jocelyn H. Leu and Elizabeth C. Hsia
The Journal of Rheumatology December 2015, jrheum.150712; DOI: https://doi.org/10.3899/jrheum.150712
Edward C. Keystone
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Mark C. Genovese
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Stephen Hall
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Sang-Cheol Bae
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Chenglong Han
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Timothy A. Gathany
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Stephen Xu
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Yiying Zhou
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Jocelyn H. Leu
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
Elizabeth C. Hsia
From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. Funded by Janssen Research & Development LLC, a wholly owned subsidiary of Johnson & Johnson, and by Merck/Schering-Plough. E.C. Keystone has received research grants, consulting fees, and honoraria from Janssen. M.C. Genovese has received research grants and consulting fees from Janssen Research & Development LLC. S. Hall and S.C. Bae have received consulting fees from Janssen Research & Development LLC. C. Han and T.A. Gathany are employees of Janssen Global Services LLC, and own stock in Johnson & Johnson. S. Xu, Y. Zhou, J.H. Leu, and E.C. Hsia are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine. Address correspondence to Dr. E.C. Keystone, Rheumatology, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 15, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial
Edward C. Keystone, Mark C. Genovese, Stephen Hall, Sang-Cheol Bae, Chenglong Han, Timothy A. Gathany, Stephen Xu, Yiying Zhou, Jocelyn H. Leu, Elizabeth C. Hsia
The Journal of Rheumatology Dec 2015, jrheum.150712; DOI: 10.3899/jrheum.150712
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial
Edward C. Keystone, Mark C. Genovese, Stephen Hall, Sang-Cheol Bae, Chenglong Han, Timothy A. Gathany, Stephen Xu, Yiying Zhou, Jocelyn H. Leu, Elizabeth C. Hsia
The Journal of Rheumatology Dec 2015, jrheum.150712; DOI: 10.3899/jrheum.150712